SAFETY DATA SHEET

Mometasone Ointment Formulation

Version: 4.1  Revision Date: 10/10/2020  SDS Number: 1751223-00008  Date of last issue: 03/23/2020  Date of first issue: 06/14/2017

SECTION 1. IDENTIFICATION

Product name: Mometasone Ointment Formulation

Manufacturer or supplier’s details

Company name of supplier: Organon & Co.
Address: 30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302
Telephone: 551-430-6000
Emergency telephone: 215-631-6999
E-mail address: EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Eye irritation: Category 2A
Reproductive toxicity: Category 1B

GHS label elements
Hazard pictograms: ⚠️ ⚠️

Signal Word: Danger

Hazard Statements: H319 Causes serious eye irritation.
H360Df May damage the unborn child. Suspected of damaging fertility.

Precautionary Statements: Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical attention.
P337 + P313 IF eye irritation persists: Get medical attention.

Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chemical name</td>
</tr>
<tr>
<td></td>
<td>Petrolatum</td>
</tr>
<tr>
<td></td>
<td>2-Methyl-2,4-pentanediol</td>
</tr>
<tr>
<td></td>
<td>Propylene glycol monostearate</td>
</tr>
<tr>
<td></td>
<td>Mometasone</td>
</tr>
</tbody>
</table>

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Causes serious eye irritation. May damage the unborn child. Suspected of damaging fertility.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Vapors may form explosive mixtures with air. Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures** : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions** : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spills cannot be contained.

**Methods and materials for containment and cleaning up** : Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

**Technical measures** : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

**Local/Total ventilation** : If sufficient ventilation is unavailable, use with local exhaust ventilation.

**Advice on safe handling** : Do not get on skin or clothing. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labeled containers. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents, Organic peroxides, Explosives, Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petrolatum</td>
<td>8009-03-8</td>
<td>TWA (Mist)</td>
<td>5 mg/m³</td>
<td>OSHA Z-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>5 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Mist)</td>
<td>5 mg/m³</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ST (Mist)</td>
<td>10 mg/m³</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td>2-Methyl-2,4-pentanediol</td>
<td>107-41-5</td>
<td>C</td>
<td>25 ppm</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>125 mg/m³</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Vapor)</td>
<td>25 ppm</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL (Vapor)</td>
<td>50 ppm</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL (Inhalable fraction, Aerosol only)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Propylene glycol monostearate</td>
<td>1323-39-3</td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: Skin

Wipe limit 10 µg/100 cm² Internal

Engineering measures: Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies.
Personal protective equipment

Respiratory protection: General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material: Chemical-resistant gloves
Remarks: Consider double gloving.

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: ointment
Color: white to off-white
Odor: No data available
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
### SECTION 10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial boiling point and boiling</td>
<td>No data available</td>
</tr>
<tr>
<td>range</td>
<td></td>
</tr>
<tr>
<td>Flash point</td>
<td>&gt; 199.9 °F / &gt; 93.3 °C</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not classified as a flammability hazard</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Upper explosion limit / Upper</td>
<td>No data available</td>
</tr>
<tr>
<td>flammability limit</td>
<td></td>
</tr>
<tr>
<td>Lower explosion limit / Lower</td>
<td>No data available</td>
</tr>
<tr>
<td>flammability limit</td>
<td></td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td></td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>No data available</td>
</tr>
<tr>
<td>Particle size</td>
<td>No data available</td>
</tr>
</tbody>
</table>

**Reactivity**
- Not classified as a reactivity hazard.

**Chemical stability**
- Stable under normal conditions.

**Possibility of hazardous reactions**
- Vapors may form explosive mixture with air.
  - Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

Petrolatum:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401
Remarks: Based on data from similar materials

Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg

Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Propylene glycol monostearate:
Acute oral toxicity: LD50 (Mouse): > 5,000 mg/kg

Mometasone:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 3.3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.
SAFETY DATA SHEET

Mometasone Ointment Formulation

Version 4.1 Revision Date: 10/10/2020 SDS Number: 1751223-00008 Date of last issue: 03/23/2020 Date of first issue: 06/14/2017

LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration):
LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Skin corrosion/irritation
Not classified based on available information.

Components:

Petrolatum:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

Propylene glycol monostearate:
Result: No skin irritation

Mometasone:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.

Components:

Petrolatum:
Species: Rabbit
Result: No eye irritation
Method: OECD Test Guideline 405
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Species: Rabbit
Result: Irritation to eyes, reversing within 21 days

Mometasone:
Species: Rabbit
Result: No eye irritation
Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Petrolatum:
Test Type: Buehler Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Test Type: Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative

Mometasone:
Test Type: Maximization Test
Routes of exposure: Dermal
Species: Guinea pig
Assessment: Does not cause skin sensitization.
Result: negative
Remarks: The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

Petrolatum:
Genotoxicity in vitro: Test Type: Chromosome aberration test in vitro
Result: negative
Remarks: Based on data from similar materials

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
**Mometasone Ointment Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>10/10/2020</td>
<td>1751223-00008</td>
<td>03/23/2020</td>
<td>06/14/2017</td>
</tr>
</tbody>
</table>

**Result:** negative

**Test Type:** In vitro mammalian cell gene mutation test  
**Method:** OECD Test Guideline 476  
**Result:** negative

**Test Type:** Chromosome aberration test in vitro  
**Result:** negative

**Mometasone:**

**Genotoxicity in vitro:**  
**Test Type:** Bacterial reverse mutation assay (AMES)  
**Result:** negative

**Test Type:** Chromosomal aberration  
**Test system:** Chinese hamster lung cells  
**Result:** negative

**Test Type:** Chromosomal aberration  
**Test system:** Chinese hamster ovary cells  
**Result:** positive

**Test Type:** Mouse Lymphoma  
**Result:** negative

**Genotoxicity in vivo:**  
**Test Type:** Micronucleus test  
**Species:** Mouse  
**Application Route:** Oral  
**Result:** negative

**Test Type:** Chromosomal aberration  
**Species:** Rat  
**Cell type:** Bone marrow  
**Result:** negative

**Test Type:** unscheduled DNA synthesis assay  
**Species:** Rat  
**Cell type:** Liver cells  
**Result:** negative

**Germ cell mutagenicity - Assessment:**  
**Weight of evidence does not support classification as a germ cell mutagen.**

**Carcinogenicity**  
**Not classified based on available information.**

**Components:**

**Petrolatum:**

**Species:** Rat  
**Application Route:** Ingestion  
**Exposure time:** 2 Years  
**Result:** negative
**SAFETY DATA SHEET**

**Mometasone Ointment Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>10/10/2020</td>
<td>1751223-00008</td>
<td>03/23/2020</td>
<td>06/14/2017</td>
</tr>
</tbody>
</table>

**Mometasone:**

- **Species**: Rat
- **Application Route**: Inhalation
- **Exposure time**: 2 Years
- **Dose**: 0.067 mg/kg body weight
- **Result**: negative

- **Species**: Mouse
- **Application Route**: Inhalation
- **Exposure time**: 19 Months
- **Dose**: 0.160 mg/kg body weight
- **Result**: negative

**IARC**

No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA**

No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

**NTP**

No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

May damage the unborn child. Suspected of damaging fertility.

**Components:**

**Petrolatum:**

- **Effects on fertility**: Test Type: Reproduction/Developmental toxicity screening test
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative
  - Remarks: Based on data from similar materials

- **Effects on fetal development**: Test Type: Embryo-fetal development
  - Species: Rat
  - Application Route: Skin contact
  - Result: negative
  - Remarks: Based on data from similar materials

**2-Methyl-2,4-pentanediol:**

- **Effects on fertility**: Test Type: Reproduction/Developmental toxicity screening test
  - Species: Rat
  - Application Route: Ingestion
  - Method: OECD Test Guideline 421
  - Result: negative

- **Effects on fetal development**: Test Type: Embryo-fetal development
  - Species: Rat
  - Application Route: Ingestion
  - Method: OECD Test Guideline 414
  - Result: negative
Mometasone:

Effects on fertility:
- Test Type: Fertility
- Species: Rat
- Application Route: Subcutaneous
- Fertility: NOAEL: 0.015 mg/kg body weight
- Symptoms: Reduced embryonic survival, Reduced fetal weight.
- Result: No effects on fertility., Effect on reproduction capacity.

Effects on fetal development:
- Test Type: Embryo-fetal development
  - Species: Mouse
  - Application Route: Subcutaneous
  - Embryo-fetal toxicity.: LOAEL: 0.06 mg/kg body weight
  - Result: Embryotoxic effects., Teratogenicity and developmental toxicity

  Test Type: Embryo-fetal development
  - Species: Rat
  - Application Route: Dermal
  - Embryo-fetal toxicity.: LOAEL: 0.3 mg/kg body weight
  - Result: Embryo-fetal toxicity.

  Test Type: Embryo-fetal development
  - Species: Rabbit
  - Application Route: Dermal
  - Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight
  - Result: Embryo-fetal toxicity., Malformations were observed.

  Test Type: Embryo-fetal development
  - Species: Rat
  - Application Route: Subcutaneous
  - Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight
  - Result: Effects on newborn.

  Test Type: Embryo-fetal development
  - Species: Rabbit
  - Application Route: Oral
  - Embryo-fetal toxicity.: LOAEL: 0.7 mg/kg body weight
  - Result: Embryo-fetal toxicity., Malformations were observed.

Reproductive toxicity - Assessment:
- Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure
- Not classified based on available information.

Components:

Mometasone:

Remarks:
- Based on available data, the classification criteria are not met.
SAFETY DATA SHEET

Mometasone Ointment Formulation

Version 4.1  Revision Date: 10/10/2020  SDS Number: 1751223-00008  Date of last issue: 03/23/2020  Date of first issue: 06/14/2017

STOT-repeated exposure
Not classified based on available information.

Components:

Mometasone:
Routes of exposure: inhalation (dust/mist/fume)
Target Organs: Immune system, Liver, Kidney, Skin
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Petrolatum:
Species: Rat
NOAEL: 5,000 mg/kg
Application Route: Ingestion
Exposure time: 2 y

2-Methyl-2,4-pentanediol:
Species: Rat
NOAEL: >= 450 mg/kg
Application Route: Ingestion
Exposure time: 90 Days
Method: OECD Test Guideline 408

Mometasone:
Species: Rat
NOAEL: 0.005 mg/kg
LOAEL: 0.3 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland
Species: Dog
LOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 30 d
Target Organs: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland
Species: Rat
NOAEL: 0.00013 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland
Species: Dog
NOAEL: 0.0005 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity
Not classified based on available information.

Components:

Mometasone:
Not applicable

Experience with human exposure

Components:

2-Methyl-2,4-pentanediol:
Eye contact: Target Organs: Eyes
Symptoms: Irritation

Mometasone:
Inhalation: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact: Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:
Remarks: Dermal absorption possible

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Petrolatum:
Toxicity to fish: LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 10,000 mg/l
Exposure time: 48 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants: NOEL (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

- NOEC (Daphnia magna (Water flea)): 10 mg/l
- Exposure time: 21 d
- Test substance: Water Accommodated Fraction
- Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:

- Toxicity to fish: LC50 (Gambusia affinis (Mosquito fish)): 8,510 mg/l
  Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates: EC50 (Ceriodaphnia dubia (water flea)): 2,800 mg/l
  Exposure time: 48 h
- Toxicity to algae/aquatic plants: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
- EC10 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
- Toxicity to microorganisms: NOEC: 200 mg/l
  Exposure time: 10 d

Mometasone:

- Toxicity to fish: LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
  Exposure time: 96 h
  Remarks: No toxicity at the limit of solubility.
- LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
  Exposure time: 7 d
  Remarks: No toxicity at the limit of solubility.
- Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 5 mg/l
  Exposure time: 48 h
  Method: OECD Test Guideline 202
  Remarks: No toxicity at the limit of solubility.
- EC50 (Americamysis): > 5 mg/l
  Exposure time: 96 h
  Method: US-EPA OPPTS 850.1035
  Remarks: No toxicity at the limit of solubility.
- Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
  Remarks: No toxicity at the limit of solubility.
- Toxicity to fish (Chronic toxicity): NOEC (Pimephales promelas (fathead minnow)): 0.00014
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

- NOEC (Daphnia magna (Water flea)): 0.34 mg/l
  - Exposure time: 21 d
  - Method: OECD Test Guideline 211
  - Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms:

- EC50: > 1,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209
  - Remarks: No toxicity at the limit of solubility.

- NOEC: 1,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209
  - Remarks: No toxicity at the limit of solubility.

Persistence and degradability

**Components:**

**Petrolatum:**

Biodegradability:

- Result: Not readily biodegradable.
- Biodegradation: 31 %
- Exposure time: 28 d
- Method: OECD Test Guideline 301F
- Remarks: Based on data from similar materials

**2-Methyl-2,4-pentanediol:**

Biodegradability:

- Result: Readily biodegradable.
- Biodegradation: 81 %
- Exposure time: 28 d
- Method: OECD Test Guideline 301F

**Mometasone:**

Biodegradability:

- Result: Not readily biodegradable.
- Biodegradation: 50 %
- Exposure time: 28 d
- Method: OECD Test Guideline 314

Stability in water:

- Hydrolysis: 50 %(12 d)
- Method: OECD Test Guideline 111

**Bioaccumulative potential**

**Components:**

**2-Methyl-2,4-pentanediol:**

Partition coefficient: n-

- log Pow: 0
octanol/water Remarks: Calculation

**Mometasone:**
Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
                Bioconcentration factor (BCF): 107.1
                Method: OECD Test Guideline 305
Partition coefficient: n-octanol/water : log Pow: 4.68

**Mobility in soil**

**Components:**

**Mometasone:**
Distribution among environmental compartments : log Koc: 4.02

**Other adverse effects**
No data available

### SECTION 13. DISPOSAL CONSIDERATIONS

**Disposal methods**
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

### SECTION 14. TRANSPORT INFORMATION

**International Regulations**

**UNRTDG**
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class : 9
Packing group : III
Labels : 9

**IATA-DGR**
UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Mometasone)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes
SAFETY DATA SHEET

Mometasone Ointment Formulation

IMDG-Code
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

49 CFR
UN/ID/NA number : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Mometasone)
Class : 9
Packing group : III
Labels : CLASS 9
ERG Code : 171
Marine pollutant : yes (Mometasone)
Remarks : Above applies only to containers over 119 gallons or 450 liters., Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Component RQ (lbs)</th>
<th>Calculated product RQ (lbs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phosphoric acid</td>
<td>7664-38-2</td>
<td>5000</td>
<td>*</td>
</tr>
</tbody>
</table>

*: Calculated RQ exceeds reasonably attainable upper limit.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Reproductive toxicity
Serious eye damage or eye irritation
SAFETY DATA SHEET

Mometasone Ointment Formulation

Version 4.1 Revision Date: 10/10/2020 SDS Number: 1751223-00008 Date of last issue: 03/23/2020 Date of first issue: 06/14/2017

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Petrolatum 8009-03-8
2-Methyl-2,4-pentanediol 107-41-5
Beeswax 8006-40-4
Water 7732-18-5

California List of Hazardous Substances

Petrolatum 8009-03-8
2-Methyl-2,4-pentanediol 107-41-5

California Permissible Exposure Limits for Chemical Contaminants

Petrolatum 8009-03-8
2-Methyl-2,4-pentanediol 107-41-5

The ingredients of this product are reported in the following inventories:

AICS: not determined

DSL: not determined

IECSC: not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:

<table>
<thead>
<tr>
<th>Flammability</th>
<th>Health</th>
<th>Instability</th>
<th>Special hazard</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® IV:

<table>
<thead>
<tr>
<th>HEALTH</th>
<th>FLAMMABILITY</th>
<th>PHYSICAL HAZARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>*</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations
**SAFETY DATA SHEET**

**Mometasone Ointment Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>10/10/2020</td>
<td>1751223-00008</td>
<td>03/23/2020</td>
<td>06/14/2017</td>
</tr>
</tbody>
</table>

**ACGIH** : USA. ACGIH Threshold Limit Values (TLV)

**NIOSH REL** : USA. NIOSH Recommended Exposure Limits

**OSHA Z-1** : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants

**ACGIH / TWA** : 8-hour, time-weighted average

**ACGIH / STEL** : Short-term exposure limit

**NIOSH REL / TWA** : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek

**NIOSH REL / ST** : STEL - 15-minute TWA exposure that should not be exceeded at any time during a workday

**NIOSH REL / C** : Ceiling value not be exceeded at any time.

**OSHA Z-1 / TWA** : 8-hour time weighted average

**AIIC** - Australian Inventory of Industrial Chemicals; **ASTM** - American Society for the Testing of Materials; **bw** - Body weight; **CERCLA** - Comprehensive Environmental Response, Compensation, and Liability Act; **CMR** - Carcinogen, Mutagen or Reproductive Toxicant; **DIN** - Standard of the German Institute for Standardisation; **DOT** - Department of Transportation; **DSL** - Domestic Substances List (Canada); **ECx** - Concentration associated with x% response; **EHS** - Extremely Hazardous Substance; **ELx** - Loading rate associated with x% response; **EmS** - Emergency Schedule; **ENCS** - Existing and New Chemical Substances (Japan); **ErCx** - Concentration associated with x% growth rate response; **ERG** - Emergency Response Guide; **GHS** - Globally Harmonized System; **GLP** - Good Laboratory Practice; **HMIS** - Hazardous Materials Identification System; **IARC** - International Agency for Research on Cancer; **IATA** - International Air Transport Association; **IBC** - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; **IC50** - Half maximal inhibitory concentration; **ICAO** - International Civil Aviation Organization; **IECSC** - Inventory of Existing Chemical Substances in China; **IMDG** - International Maritime Dangerous Goods; **IMO** - International Maritime Organization; **ISHL** - Industrial Safety and Health Law (Japan); **ISO** - International Organisation for Standardization; **KECI** - Korea Existing Chemicals Inventory; **LC50** - Lethal Concentration to 50 % of a test population; **LD50** - Lethal Dose to 50% of a test population (Median Lethal Dose); **MARPOL** - International Convention for the Prevention of Pollution from Ships; **MSHA** - Mine Safety and Health Administration; **n.o.s.** - Not Otherwise Specified; **NFPA** - National Fire Protection Association; **NO(A)EC** - No Observed (Adverse) Effect Concentration; **NO(A)EL** - No Observed (Adverse) Effect Level; **NOELR** - No Observable Effect Loading Rate; **NTP** - National Toxicology Program; **NZIoC** - New Zealand Inventory of Chemicals; **OECD** - Organization for Economic Co-operation and Development; **OPPTS** - Office of Chemical Safety and Pollution Prevention; **PBT** - Persistent, Bioaccumulative and Toxic substance; **PICCS** - Philippines Inventory of Chemicals and Chemical Substances; **(Q)SAR** - (Quantitative) Structure Activity Relationship; **RCRA** - Resource Conservation and Recovery Act; **REACH** - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; **RO** - Reportable Quantity; **SADT** - Self-Accelerating Decomposition Temperature; **SARA** - Superfund Amendments and Reauthorization Act; **SDS** - Safety Data Sheet; **TCSI** - Taiwan Chemical Substance Inventory; **TSCA** - Toxic Substances Control Act (United States); **UN** - United Nations; **UNRTDG** - United Nations Recommendations on the Transport of Dangerous Goods; **vPvB** - Very Persistent and Very Bioaccumulative


**Revision Date** : 10/10/2020
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8